YD Bio Limited Ordinary Shares (YDES) Financial Analysis & Valuation | Quarter Chart
YD Bio Limited Ordinary Shares (YDES)
YDESPrice: $5.44
Fair Value: 🔒
🔒score
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Tai... more
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on ... more
Description
Shares
| Market Cap | $383.64M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | TW | CEO | Ethan Shen |
| IPO Date | 2025-08-29 | CAGR | — |
| Employees | 4 | Website | www.ydesgroup.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 21.91% | Total Yield | 21.91% |
YDES chart loading...
Fundamentals
Technicals
| Enterprise Value | $-234.69M | P/E Ratio | -272 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -43.87 |
| P/CF Ratio | -594.58 | P/FCF Ratio | -12297.57 |
| EPS | $-0.02 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | 0.28% | ROA | -1.01% |
| ROCE | 0.17% | Current Ratio | 0.02 |
| Quick Ratio | 0.02 | Cash Ratio | — |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | 0.05 | Piotroski Score | 2 |